News

Dr Reddy's partner Immutep told to halt phase III trial of lung cancer drug eftilagimod alfaEnrolment in the study is being halted in response to the Independent Data Monitoring Committee's recommendation. Shares of Dr Reddy's Laboratories Ltd ended at ₹1,288.40, down by ₹30.35, or 2.30%, on the BSE today, March 13.By Jomy Jos Pullokaran  March 14, 2026, 9:04:27 AM IST (Updated)2 Min ReadHyderabad-based drug maker Dr Reddy’s Laboratories Ltd on Friday (March 13) said its licensing partner Immutep has discontinued the Phase III TACTI-004 clinical trial evaluating Eftilagimod alfa (efti) in patients with first-line non-small cell lung cancer following a recommendation from the Independent Data Monitoring Committee (IDMC).

The recommendation came after a planned interim futility analysis in which the committee reviewed available safety and efficacy data from the study. Based on this assessment, the IDMC advised discontinuing the trial in accordance with the study protocol.

Following the recommendation, enrolment in the study will be halted, and Immutep will initiate an orderly wind-down of the trial. This process will include appropriate patient follow-up and closure of study sites in line with regulatory and ethical obligations.

Also Read: Delhi HC rejects Novo Nordisk plea to restrain Dr Reddy’s from exporting semaglutide

The update comes in reference to the company’s earlier disclosure dated December 8, 2025, when Dr Reddy’s Laboratories SA, a wholly owned subsidiary of the company, entered into a strategic collaboration and exclusive licensing agreement with Immutep SAS to develop and commercialise Eftilagimod alfa in all countries outside North America, Europe, Japan and Greater China.

Dr Reddy’s said its subsidiary has so far made only the upfront payment to Immutep under the collaboration agreement. The company added that Dr Reddy’s SA continues to engage with Immutep to determine the appropriate way forward following the development.

Immutep has also initiated a comprehensive review of the available trial data to better understand the outcome and determine the next steps for the program.

Shares of Dr Reddy's Laboratories Ltd ended at ₹1,288.40, down by ₹30.35, or 2.30%, on the BSE today, March 13.

Also Read: Explained | Here's why Dr Reddy's Laboratories shares have recovered 3% from their day's lowsContinue Reading(Edited by : Shoma Bhattacharjee)First Published: Mar 13, 2026 8:10 PM ISTTagsDr Reddy’s Labshare market today